Activity of VT-464, a selective CYP17 lyase inhibitor, in the LNCaP prostate cancer xenograft model.
Stephen Todd Pisle
No relevant relationships to disclose
Heather M Pressler
No relevant relationships to disclose
Sarah M Troutman
No relevant relationships to disclose
Joel Robert Eisner
Employment or Leadership Position - Viamet Pharmaceuticals
Stephen W Rafferty
Employment or Leadership Position - Viamet Pharmaceuticals
Robert J Schotzinger
Employment or Leadership Position - Viamet Pharmaceuticals
William R Moore
Employment or Leadership Position - Viamet Pharmaceuticals
William Douglas Figg
No relevant relationships to disclose